Cheon Young-Jun, Jung Tae-Young, Jung Shin, Kim In-Young, Moon Kyung-Sub, Lim Sa-Hoe
Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine, Hwasun, Korea.
J Korean Neurosurg Soc. 2018 Jul;61(4):516-524. doi: 10.3340/jkns.2017.0259. Epub 2018 Jul 1.
This study aims to determine whether gamma knife radiosurgery (GKR) improves survival in patients with recurrent highgrade gliomas.
Twenty nine patients with recurrent high-grade glioma underwent 38 GKR. The male-to-female ratio was 10 : 19, and the median age was 53.8 years (range, 20-75). GKR was performed in 11 cases of recurrent anaplastic oligodendrogliomas, five anaplastic astrocytomas, and 22 glioblastomas. The median prescription dose was 16 Gy (range, 10-24), and the median target volume was 7.0 mL (range, 1.1-15.7). Of the 29 patients, 13 (44.8%) received concurrent chemotherapy. We retrospectively analyzed the progression-free survival (PFS) and overall survival (OS) after GKR depending on the Eastern Cooperative Oncology Group (ECOG) performance status (PS), pathology, concurrent chemotherapy, radiation dose, and target tumor volume.
Starting from when the patients underwent GKR, the median PFS and OS were 5.0 months (range, 1.1-28.1) and 13.0 months (range, 1.1-75.1), respectively. On univariate analysis, the median PFS was significantly long in patients with anaplastic oligodendroglioma, ECOG PS 1, and target tumor volume less than 10 mL (p<0.05). Meanwhile, on multivariate analysis, patients with ECOG PS 1 and target tumor volume less than 10 mL showed improved PFS (p=0.043 and p=0.007, respectively). The median OS was significantly increased in patients with ECOG PS 1 and tumor volume less than 10 mL on univariate and multivariate analyses (p<0.05).
GKR could be an additional treatment option in recurrent high-grade glioma, particularly in patients with good PS and limited tumor volume.
本研究旨在确定伽玛刀放射外科手术(GKR)是否能提高复发性高级别胶质瘤患者的生存率。
29例复发性高级别胶质瘤患者接受了38次GKR治疗。男女比例为10:19,中位年龄为53.8岁(范围20 - 75岁)。11例复发性间变性少突胶质细胞瘤、5例间变性星形细胞瘤和22例胶质母细胞瘤患者接受了GKR治疗。中位处方剂量为16 Gy(范围10 - 24),中位靶体积为7.0 mL(范围1.1 - 15.7)。29例患者中,13例(44.8%)接受了同步化疗。我们根据东部肿瘤协作组(ECOG)的体能状态(PS)、病理、同步化疗、放射剂量和靶肿瘤体积,回顾性分析了GKR术后的无进展生存期(PFS)和总生存期(OS)。
从患者接受GKR治疗开始计算,中位PFS和OS分别为5.0个月(范围1.1 - 28.1)和13.0个月(范围1.1 - 75.1)。单因素分析显示,间变性少突胶质细胞瘤患者、ECOG PS为1且靶肿瘤体积小于10 mL的患者中位PFS显著延长(p<0.05)。同时,多因素分析显示,ECOG PS为1且靶肿瘤体积小于10 mL的患者PFS改善(分别为p = 0.043和p = 0.007)。单因素和多因素分析均显示,ECOG PS为1且肿瘤体积小于10 mL的患者中位OS显著延长(p<0.05)。
GKR可以作为复发性高级别胶质瘤的一种额外治疗选择方案,尤其是对于PS良好且肿瘤体积有限的患者。